


Respiratory Therapy ED Asthma Treatment Guideline (Age >= 12 years)



*Risk factors for fatal asthma:

- Comorbidities (cardiovascular disease, other chronic lung disease)
- Illicit drug use
- Low socioeconomic status/inner-city residence
- Major psychosocial problems/psychiatric disorders
- Previous severe exacerbations (ie: intubation or admission to ICU for asthma)
- 2+ hospitalizations in the last year
- 3+ ED visits in the last year
- Hospitalization or ED visit asthma in the past month
- 2+ refills of short-acting Beta 2 agonists per month
- Difficulty perceiving asthma symptoms or severity of exacerbations

Adapted from the National Heart Lung and Blood Institute. National Asthma Education and Prevention Program. Expert panel report 3: Guidelines for the diagnosis and management of asthma; 2007:377. <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>.

References

- Camargo CA, Jr, Gurner DM, Smithline HA, Chapela R, Fabbri LM, Green SA, et al. A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. *J Allergy Clin Immunol*. 2010;125:374–80.
- Emerman CL, Cydulka RK. A randomized comparison of 100-mg vs 500-mg dose of methylprednisolone in the treatment of acute asthma. *Chest* 1995; 107:1559.
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention (2018 update). www.ginasthma.org (Accessed on September 25, 2018).
- Manser R, Reid D, Abramson M. Corticosteroids for acute severe asthma in hospitalized patients. *Cochrane Database Syst Rev*. 2001;1:CD001740.
- McFadden ER Jr. Acute severe asthma. *Am J Respir Crit Care Med* 2003; 168:740.
- Morris CR, Becker AB, Piñeiro A, Massaad R, Green SA, Smugar SS, et al. A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma. *Ann Allergy Asthma Immunol*. 2010;104:161–71.
- National Asthma Education and Prevention Program: Expert Panel Report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD. National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 19, 2018).
- Normansell R, Kew KM, Mansour G. Different oral corticosteroid regimens for acute asthma. *Cochrane Database Syst Rev* 2016; :CD011801.
- Parameswaran K, Belda J, Rowe BH. Addition of intravenous aminophylline to beta2-agonists in adults with acute asthma. *Cochrane Database Syst Rev*. 2000:CD002742.
- Rowe BH, Edmonds ML, Spooner CH, Diner B, Camargo CA. Corticosteroid therapy for acute asthma. *Respiratory Medicine*. 2004;98:275-284.
- Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. *Cochrane Database Syst Rev*. 2001:CD002178.
- Todi VK, Lodha R, Kabra SK. Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: A randomised, double-blind, placebo controlled trial. *Arch Dis Child*. 2010;95:540–3.
- Travers AH, Rowe BH, Barker S, Jones A, Camargo CA., Jr The effectiveness of IV beta-agonists in treating patients with acute asthma in the emergency department: A meta-analysis. *Chest*. 2002;122:1200–7

US Department of Health and Human Services, National Institute of Health, National Heart, Lung, and Blood Institute. Expert Panel Report 3: guidelines for the diagnosis and management of asthma [Accessed April 8, 2008]. Available from: <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf>.